MedImmune's historical roots are in infectious disease. In 1998 we were the
first company to launch a
monoclonal antibody in the United States targeting an infectious
disease. This product, Synagis® (palivizumab), today produces more than $1 billion in revenues worldwide and more than 1 million doses have been distributed.
The company is also developing a vaccine to help prevent RSV, the most common
cause of hospitalizations in children under one year of age, and
is investigating whether antibodies can be used to treat infants hospitalized
with this virus.
In 2008, MedImmune filed with the U.S. Food and Drug Administration for approval
of an anti-RSV antibody, motavizumab.
MedImmune is driving innovation, having introduced in 2003 the first vaccine to use cutting-edge attenuated live virus technology (FluMist®[Influenza Vaccine Live, Intranasal]). In
2007, we improved the formulation of FluMist®, which significantly
improved the storage and handling requirements for the vaccine. We also successfully expanded the label of the vaccine. We continually strive to seek ways to improve our technology and we're also exploring its role in helping prevent worldwide pandemics.
We are also exploring ways of bringing biologic
technology to the most challenging infectious disease needs of our society.
Research is ongoing in such diverse areas as herpes viruses, hepatitis C virus,
antibacterials, and other respiratory viruses.